mRNA: A promising platform for cancer immunotherapy

Byoungjae Kong; Yelee Kim; Eun Hye Kim; Jung Soo Suk; Yoosoo Yang

doi:10.1016/j.addr.2023.114993

mRNA: A promising platform for cancer immunotherapy

Adv Drug Deliv Rev. 2023 Aug:199:114993. doi: 10.1016/j.addr.2023.114993. Epub 2023 Jul 4.

Authors

Byoungjae Kong¹, Yelee Kim², Eun Hye Kim², Jung Soo Suk³, Yoosoo Yang⁴

Affiliations

¹ Center for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
² Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea; Department of Life Sciences, Korea University, Seoul 02841, Republic of Korea.
³ Center for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA. Electronic address: jsuk@jhmi.edu.
⁴ Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea. Electronic address: ysyang@kist.re.kr.

PMID: 37414361
DOI: 10.1016/j.addr.2023.114993

Abstract

Messenger RNA (mRNA) is now in the limelight as a powerful tool for treating various human diseases, especially malignant tumors, thanks to the remarkable clinical outcomes of mRNA vaccines using lipid nanoparticle technology during the COVID-19 pandemic. Recent promising preclinical and clinical results that epitomize the advancement in mRNA and nanoformulation-based delivery technologies have highlighted the tremendous potential of mRNA in cancer immunotherapy. mRNAs can be harnessed for cancer immunotherapy in forms of various therapeutic modalities, including cancer vaccines, adoptive T-cell therapies, therapeutic antibodies, and immunomodulatory proteins. This review provides a comprehensive overview of the current state and prospects of mRNA-based therapeutics, including numerous delivery and therapeutic strategies.

Publication types

Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

COVID-19* / therapy
Humans
Immunotherapy / methods
Neoplasms*
Pandemics
RNA, Messenger

Substances

RNA, Messenger

Abstract

Publication types

MeSH terms

Substances

Grants and funding